Advertisement
Advertisement

ANTX

ANTX logo

AN2 Therapeutics, Inc. Common Stock

1.13
USD
Sponsored
-0.03
-2.94%
Jan 29, 14:55 UTC -5
Closed
exchange

Pre-Market

1.14

+0.01
+0.53%

ANTX Earnings Reports

Positive Surprise Ratio

ANTX beat 9 of 15 last estimates.

60%

Next Report

Date of Next Report
Mar 16, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.24
Implied change from Q3 25 (Revenue/ EPS)
--
/
-22.58%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-4.00%

AN2 Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, ANTX reported earnings of -0.31 USD per share (EPS) for Q3 25, missing the estimate of -0.22 USD, resulting in a -38.15% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.24% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.24 USD, with revenue projected to reach -- USD, implying an decrease of -22.58% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, AN2 Therapeutics, Inc. Common Stock reported EPS of -$0.31, missing estimates by -38.15%, and revenue of $0.00, 0% as expectations.
The stock price moved down -4.24%, changed from $1.18 before the earnings release to $1.13 the day after.
The next earning report is scheduled for Mar 16, 2026.
Based on 3 analysts, AN2 Therapeutics, Inc. Common Stock is expected to report EPS of -$0.24 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement